143558-00-3 | Rocuronium

Chemical type

• Non-depolarizing muscle relaxant (NDMR)

^[1]

• Non-depolarizing neuromuscular blocker (aminosteroid)

^[2]

Key properties

• Dose-dependent inhibitor of twitch tensions in skeletal muscle
• IC₅₀ increased by burn injuries (e.g., from ~566 µg/kg in sham to ~795 µg/kg in burned legs)
• Resistance induced by burns reversed by HDAC4 inhibition
• Administered intravenously in incremental doses (100-3200 µg/kg)

^[1]

• Blocks acetylcholine at neuromuscular junction
• Intermediate duration of action

^[2]

• Muscle relaxant for anesthesia in burn-injured patients to facilitate intubation and surgery
• Assessed for potency in tension tests post-burn injury
• Tool to study NDMR resistance mechanisms in skeletal muscle

^[1]

• Muscle relaxation for intubation (0.6 mg/kg intravenous) during anesthesia induction

^[2]

Classification by use

• Chemicals used as neuromuscular blocking agents
• Chemicals used in anesthesiology
• Chemicals used in burn injury pharmacology research

^[1]

• Neuromuscular blocking agents

^[2]

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] Trichostatin A reverses rocuronium resistance in burn-injured rats, Burns, Volume 51, Issue 2, March 2025, 107351
2. [Cite:2] Lidocaine mitigates cognitive decline in elderly patients after video-assisted thoracoscopic surgery: A double-blind randomized controlled clinical trial, Brain Disorders, Volume 21, March 2026, 100308